JPMorgan Chase & Co. cut its position in shares of Qiagen NV (NASDAQ:QGEN) by 19.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 504,292 shares of the company’s stock after selling 123,890 shares during the period. JPMorgan Chase & Co. owned about 0.22% of Qiagen NV worth $10,998,000 as of its most recent filing with the SEC.
Several other large investors also recently added to or reduced their stakes in the stock. Stephens Inc. AR increased its stake in Qiagen NV by 14.5% in the second quarter. Stephens Inc. AR now owns 8,255 shares of the company’s stock worth $180,000 after buying an additional 1,043 shares during the period. Fuller & Thaler Asset Management Inc. bought a new stake in Qiagen NV during the second quarter worth about $116,000. Manning & Napier Advisors LLC increased its stake in Qiagen NV by 31.7% in the second quarter. Manning & Napier Advisors LLC now owns 6,111,364 shares of the company’s stock worth $133,287,000 after buying an additional 1,470,315 shares during the period. Aviva PLC increased its stake in Qiagen NV by 37.8% in the second quarter. Aviva PLC now owns 195,350 shares of the company’s stock worth $4,230,000 after buying an additional 53,570 shares during the period. Finally, Timber Hill LLC bought a new stake in Qiagen NV during the second quarter worth about $219,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.
Shares of Qiagen NV (NASDAQ:QGEN) traded up 0.29% on Tuesday, hitting $27.35. 465,836 shares of the stock traded hands. The firm has a market cap of $6.40 billion, a P/E ratio of 54.70 and a beta of 0.83. The firm’s 50-day moving average is $26.80 and its 200 day moving average is $23.68. Qiagen NV has a 12-month low of $19.94 and a 12-month high of $28.04.
Qiagen NV (NASDAQ:QGEN) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.01. Qiagen NV had a net margin of 9.13% and a return on equity of 9.21%. The firm had revenue of $334.40 million for the quarter, compared to analyst estimates of $326.73 million. During the same quarter last year, the firm posted $0.26 earnings per share. Qiagen NV’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities research analysts forecast that Qiagen NV will post $1.09 EPS for the current fiscal year.
A number of research firms have recently issued reports on QGEN. DZ Bank AG reissued a “buy” rating on shares of Qiagen NV in a research note on Monday, September 19th. Commerzbank AG restated a “buy” rating on shares of Qiagen NV in a report on Friday, September 16th. Zacks Investment Research upgraded shares of Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a report on Wednesday, September 14th. Morgan Stanley set a $30.00 price objective on shares of Qiagen NV and gave the company a “buy” rating in a report on Sunday, September 11th. Finally, Jefferies Group restated a “hold” rating on shares of Qiagen NV in a report on Thursday, August 4th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $25.36.
About Qiagen NV
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.